6 August 2025
Swissmedic: Study confirms Swissmedic's competitiveness
A study conducted by the Centre for Innovation in Regulatory Science (CIRS) has found that Swissmedic's authorisation procedures for human medicinal products with new active substances are internationally competitive. Swissmedic was ranked second behind Japan in terms of the scientific assessment time, and on par with the European Medicines Association (EMA) regarding the total throughout time.
CIRS is an independent organisation specialising in the promotion of regulatory science. Its goal is to define global standards for the authorisation of medicinal products and accelerate market access to medicines. Each year, CIRS analyses and compares the authorisation processes for innovative medicines with new active substances from six leading regulatory authorities: EMA, FDA, PMDA, Health Canada, TGA, and Swissmedic.
For more information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Swissmedic: Haemovigilance Annual Report 2025
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
European Medicines Agency: Highlights of the September 2026 Management Board meeting